Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Stéphane Champiat(Université Paris-Saclay), Aurélien Marabelle(Université Paris-Saclay)
Cited by 5
Related Papers
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
|Nature Reviews Clinical Oncology|2021|469
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
|Journal of Experimental & Clinical Cancer Research|2022|28